Return on investment of Canadian tobacco control policies implemented between 2001 and 2016.


Journal

Tobacco control
ISSN: 1468-3318
Titre abrégé: Tob Control
Pays: England
ID NLM: 9209612

Informations de publication

Date de publication:
03 2023
Historique:
received: 07 01 2021
accepted: 12 07 2021
pubmed: 12 8 2021
medline: 25 2 2023
entrez: 11 8 2021
Statut: ppublish

Résumé

To determine the return on investment (ROI) associated with tobacco control policies implemented between 2001 and 2016 in Canada. Canadian expenditures on tobacco policies were collected from government sources. The economic benefits considered in our analyses (decrease in healthcare costs, productivity costs and monetised life years lost, as well as tax revenues) were based on the changes in smoking prevalence and attributable deaths derived from the SimSmoke simulation model for the period 2001-2016. The net economic benefit (monetised benefits minus expenditures) and ROI associated with these policies were determined from the government and societal perspectives. Sensitivity analyses were conducted to check the robustness of the result. Costs were expressed in 2019 Canadian dollars. The total of provincial and federal expenditures associated with the implementation of tobacco control policies in Canada from 2001 through 2016 was estimated at $2.4 billion. Total economic benefits from these policies during that time were calculated at $49.2 billion from the government perspective and at $54.2 billion from the societal perspective. The corresponding ROIs were $19.8 and $21.9 for every dollar invested. Sensitivity analyses yielded ROI values ranging from $16.3 to $28.3 for every dollar invested depending on the analyses and perspective. This analysis has found that the costs to implement the Canadian tobacco policies between 2001 and 2016 were far outweighed by the monetised value associated with the benefits of these policies, making a powerful case for the investment in tobacco control policies.

Identifiants

pubmed: 34376563
pii: tobaccocontrol-2021-056473
doi: 10.1136/tobaccocontrol-2021-056473
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

233-238

Informations de copyright

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Jean-Eric Tarride (JE)

Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada tarride@mcmaster.ca.
Center for Health Economics and Policy Analysis (CHEPA), McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada.
Programs for Assessment of Technologies in Health, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.

Gord Blackhouse (G)

Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada.
Center for Health Economics and Policy Analysis (CHEPA), McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada.
Programs for Assessment of Technologies in Health, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.

G Emmanuel Guindon (GE)

Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada.
Center for Health Economics and Policy Analysis (CHEPA), McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada.

Michael O Chaiton (MO)

Dalla Lana School of Public Health, Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Institute for Mental Health Policy Research, Center for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
Ontario Tobacco Research Unit, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Lynn Planinac (L)

Dalla Lana School of Public Health, Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Ontario Tobacco Research Unit, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Robert Schwartz (R)

Dalla Lana School of Public Health, Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Institute for Mental Health Policy Research, Center for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
Ontario Tobacco Research Unit, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH